Search

Cilastatin

Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. … [L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894]

LI-301

LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. … It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors.

Avanafil

[L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113] … Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction.

Fructose

Resmetirom

On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD.

Trapidil

Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

Bevacizumab

[A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically … [A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021.

Carbopol 974P

The compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … Carbopol 974P is a highly carboxylated polymer composed of lightly cross-linked polyacrylic acid with a broad-spectrum mechanism based on acidification of pathogens.

Ouabain

It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.

Elvitegravir

Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.